ImmunoCellular Therapeutics (NYSE MKT: IMUC) announced today that
clinical data from its Phase I trial of ICT-107 was accepted for
publication, and is currently in the online edition of the prestigious
medical journal Cancer Immunology, Immunotherapy (http://www.springerlink.com/content/n0018574g9m4v587/fulltext.pdf).
In the publication, the data showed that the expression of four ICT-107
targeted antigens in the pre-vaccine tumors correlated with longer
overall survival (OS) and progression free survival (PFS) in newly
diagnosed glioblastoma multiforme (GBM) patients. Median PFS in newly
diagnosed GBM patients was 16.9 months and median OS was 38.4 months.
Tumors from post-vaccine resections in five patients showed a decrease
in or loss of the cancer stem cell associated antigen CD133 relative to
their pre-vaccine counterparts, which may be promising because previous
studies have consistently shown increased expression of CD133 in
recurrent tumors. The idea of cancer stem cell therapeutics has received
increasing attention, including through publications noting IMUC's
progress in the clinic with its ICT-107 vaccine targeting antigens
associated with cancer stem cells and articles in the recent issues of Nature and
Science noting the significance of cancer stem cells to tumor
In the Phase I study to evaluate the safety and immune responses to
ICT-107, 21 patients were enrolled, including 17 newly diagnosed (16
evaluable as one did not receive any treatment) and three recurrent GBM
patients and one with brainstem glioma. Tumor associated antigen
expression analysis showed all patients had at least three of the
antigens and 75% had all six of the antigens targeted by ICT-107. At a
median follow-up of 40.1 months, six of the newly diagnosed patients
showed no evidence of tumor recurrence. "We are extremely pleased that
our clinical results were accepted for publication," said Manish Singh,
Ph.D., ImmunoCellular's president and CEO. "The publication of the data
in yet another respected medium, as well as the recent Nature articles
detailing the importance of cancer stem cells to tumor growth, validate
the potential of our clinical programs for the treatment of patients
with either newly diagnosed or recurrent GBM."
ImmunoCellular Therapeutics, Ltd.